By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
RESI Boston returns on September 17, 2025 at the Westin Copley Place, once again serving as a core event during Biotech Week Boston. Organized by Life Science Nation, RESI (Redefining Every Stage of Investment) brings together life science and healthcare companies with hundreds of investors and strategic partners for a day of partnering, networking, educational content, and exhibits.
A highlight of every RESI conference is the investor panel programming, where active investors and strategics speak directly to entrepreneurs about what they’re looking for, how they invest, and how startups can position themselves for success. The upcoming September event will feature deep dives into some of the most dynamic areas of healthcare innovation, featuring speakers from impact investors, corporate venture arms, Big Pharma, family offices, and more.
Impact Investors & Venture Philanthropy Panel
The Role of Impact Investing in the Healthcare Ecosystem
Impact investors and venture philanthropists are playing a growing role in backing early-stage healthcare ventures, especially those addressing health equity and underserved areas. In this panel, leaders in the field will discuss how they define and measure impact, what they look for in mission-driven ventures, and how they work with founders to align values with milestone-based progress. Attendees will gain insight into how this capital is deployed to catalyze innovations that go beyond traditional ROI.
Mental & Behavioral Health Panel
Investing in Solutions for Higher Quality of Life and Wellbeing
With 1 in 8 people globally affected by mental disorders, demand for novel solutions in behavioral health continues to grow. This panel features investors who are actively backing companies developing digital tools, neurotechnologies, care delivery innovations, and novel therapeutics. Panelists will explore challenges such as stigma, reimbursement, and regulation—along with what it takes for startups to stand out in this vital and rapidly evolving market.
Oncology Innovation Panel
Latest Scientific Breakthroughs and Future Outlook
Oncology continues to attract robust investor interest, yet the bar for scientific rigor and differentiation is high. This session gathers investors focused on oncology diagnostics, therapeutics, and platforms to discuss what excites them in the current landscape and what it takes to succeed. Topics include scientific novelty, clinical de-risking, commercial potential, and where the next wave of oncology innovation may arise.
Corporate VC Panel
Venture and Innovation Arms Making Strategic Investments
Corporate VCs offer much more than capital, they bring strategic alignment, deep expertise, and long-term partnership opportunities. In this session, leaders from CVC arms of major pharma, biotech, and medtech companies will discuss how they source and evaluate early-stage deals, what startups should expect post-investment, and how founders can navigate alignment with a corporate parent. This panel is essential for startups seeking strategic investors.
Diagnostics Panel
Investing in Innovations for Preventative and Personalized Care
As diagnostics become increasingly central to precision medicine and population health, investors are paying close attention. Panelists in this session will discuss how they evaluate new diagnostic technologies, from regulatory and reimbursement outlooks to commercial differentiation and unmet need. For entrepreneurs developing platforms in oncology, infectious disease, or chronic conditions, this discussion will provide actionable guidance on positioning and funding strategies.
Partnering with Big Pharma Panel
What Startups Need to Know to Get on Big Pharma’s Radar
Securing a partnership with Big Pharma can be a transformative milestone. This panel features business development and venture leaders from leading pharmaceutical companies who will share what they look for in early-stage collaborations. Learn how they assess risk, stage readiness, and strategic fit—plus how startups can build compelling cases for co-development, licensing, or investment.
Family Offices Panel
Perspectives on Early-Stage Investments
Family offices have become increasingly visible in early-stage healthcare deals, often offering patient capital and values-driven investment strategies. This panel will unpack how these investors approach opportunity evaluation, what sets them apart from traditional VCs, and how they support portfolio companies beyond capital. Attendees will also hear practical advice for engaging family offices and building meaningful relationships.
Whether you’re developing breakthrough diagnostics, therapeutics, platforms, or care delivery solutions, the RESI Boston investor panels offer a unique opportunity to hear directly from the funders shaping the future of healthcare.
Interested in sharing your insights at RESI? Reach out to join our speaker lineup!
Register by July 11 to lock in Super Early Bird Rates and save $300. Secure your spot today and join 400+ investors and strategic partners this September in Boston.
Tags: business, entrepreneurship, finance, startups, technology, venture capital
Pre-pandemic I came across a survey that went out to in-licensors and investors to see from where they sourced their deals. Pipeline databases? Literature? Partnering meetings? Medical conferences? Incoming email solicitations? Website submissions? Warm intros? As it happens, the #1 answer was partnering events, representing the first point of contact for the two parties that eventually made a deal. Even the BioNTech and Pfizer deal came out of a partnering conference in 2013.
Next Phase Newsletter 